- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Locanabio Inc.
Headquarters: San Diego, CA, United States of America
Website: N/A
Year Founded: 2016
Status: Out of Business
BioCentury | Dec 10, 2024
Management Tracks
Toshinori Agatsuma, Daiichi’s head of research, passes away
Plus: Lange becomes CBO of Avidity and updates from CABS, BIO, Zevra and Achieve
BioCentury | Jan 30, 2024
Product Development
Singapore’s next challenge: turning momentum into sustainable growth
The island nation has caught the interest of international investors and pharmas. Will this be the moment its biotech accelerates?
BioCentury | Aug 2, 2022
Management Tracks
Mackison named CEO at Vico
Plus Arvinas hires Northcott as CCO, Manion joins Aclaris and updates from AnHeart, Gracell, Find and more
BioCentury | Jun 7, 2022
Management Tracks
Franklin becomes president and COO at PureTech’s Akili
Plus new CMOs at Artiva and Third Harmonic, and updates from Dotmatics
BioCentury | May 20, 2022
Discovery & Translation
Precision’s chronic HBV gene therapy; plus Blaze and ASGCT highlights
BioCentury’s roundup of translational news
BioCentury | Apr 6, 2022
Data Byte
Wave next up in the C9orf72 pipeline
Four other therapies in preclinical development for ALS or FTD
BioCentury | Sep 9, 2021
Management Tracks
Hayes joins Fulcrum as chief commercial officer
Plus: ImmunityBio, Finch, Rhythm, Infinity, Locanabio and more
BioCentury | Jul 8, 2021
Management Tracks
Chin returns to Arix to rebuild investment team as three more depart; plus ADCendo, Magenta, Junshi, Valneva, Q32 Bio, Outlook, Quotient Catalyst, Kaleido, Amolyt and more
Mark Chin is rejoining Arix Bioscience plc (LSE:ARIX) as managing director with a mandate to rebuild the VC’s investment team. Managing Director Christian Schetter, Principal John Cassidy
BioCentury | Dec 15, 2020
Finance
Dec. 14 Quick Takes: Locanabio raises $100M series B; plus rare bleeding disorder newco Hemab, raises for Rani, CG, InnoSkel, Denovo, Biosion and more
Vida leads Locanabio’s $100M B roundLocanabio Inc. raised $100 million in a series B financing led by Vida Ventures, with participation from new investors RA Capital, Invus, Acuta Capital
BioCentury | Sep 19, 2020
Translation in Brief
Gene therapies from Passage Bio, Locanabio; Lava’s antitumor bispecific, health disparities in Alzheimer’s and more
BioCentury’s roundup of translational news
Items per page:
1 - 10 of 18